Ground-breaking Thalassemia Clinical Trials to Begin in Abu Dhabi

Ground-breaking Thalassemia Clinical Trials to Begin in Abu Dhabi

- Trials will provide an opportunity for eligible patients in the region to get screened and be part of studies aimed at developing new thalassemia treatment

Abu Dhabi, UAE – As an incubator and hub for life-science research and innovation, Abu Dhabi is set to begin clinical trials to transform the way thalassemia is being treated, kicking it off with two global clinical trials. Under the Department of Health - Abu Dhabi’s (DoH) supervision and support, the “Phase 3” trials for adult patients with thalassemia, ENERGIZE and ENERGIZE-T aim to test the effectiveness and safety of a new drug, Mitapivat. Conducted at Abu Dhabi-based Burjeel Medical City, the clinical trials offer new hope for thalassemia patients in the country. The trials will be conducted in collaboration with several centres and multiple sites across the United States of America (USA), the European Union (EU), and Asia, enabling access to state-of-the-art therapies from the outset of clinical development.

Mitapivat (Agios Pharmaceuticals; MA, USA) is already approved in the USA and the EU for managing hemolytic anemia in adults with pyruvate kinase deficiency, however, recently, it has also demonstrated potential in earlier trials for the treatment of thalassemia.

In the upcoming stage, the “Phase 3” program